key: cord-0799120-ucmmzhym
authors: Edeas, Marvin; Saleh, Jumana; Peyssonnaux, Carole
title: Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?
date: 2020-06-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.05.110
sha: 9bd540ebb0b4c5c0bbc590c5cd1cda12aa6f4e85
doc_id: 799120
cord_uid: ucmmzhym

The coronavirus 2 (SARS-CoV-2) pandemic is viciously spreading through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on that respiratory failure is the leading cause of mortality. However, mounting evidence link accelerated pathogenesis in gravely ill COVID-19 patients to a hyper-inflammatory state involving a cytokine storm. Several components of the heightened inflammatory state were addressed as therapeutic targets. Another key component of the heightened inflammatory state is hyper-ferritinemia which reportedly identifies patients with increased mortality risk. In spite of its strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis. Here we address implications of a possible role for hyper-ferritinemia, and altered iron homeostasis in COVID-19 pathogenesis, and potential therapeutic targets in this regard.

IntroductionThe coronavirus 2019 pandemic has taken the world by surprise as it viciously spread through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on that respiratory failure is the leading cause of fatalities (Zhou et al. 2020) . Nevertheless, mounting evidence points to drastic systemic events taking place that contribute to accelerated COVID-19 pathogenesis. The "cytokine storm" is a notion that is reportedly hailed as the hallmark of the COVID-19 hyper-inflammatory state (Mehta et al. 2020) . Consecutive studies linked COVID-19 related hyper-inflammation to systemic events including; hypercoagulability, oxidative stress and altered iron metabolism (Mehta et al. 2020; Phua et al. 2020) . These events were linked to accelerated pathogenesis in gravely ill COVID-19 patients as highlighted in a recent perspective (Moore and June 2020) . Several components of the heightened inflammatory state have been proposed as therapeutic targets particularly IL-6 blockers as drugs of more relevance in COVID-19 management than steroids, however concerns of prolonging viral clearance were stated (Moore and June 2020).

Hyper-ferritinemia, has been described as a cardinal feature that predicted with high significance the increased mortality risk (Mehta et al. 2020; Phua et al. 2020 ). These studies demonstrated serum ferritin levels in COVID-19 non-survivors that exceeded "two-fold" the levels in the survivors. In spite of the strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis.

Recently we showed that hepcidin, the key iron regulatory molecule, plays a major role during inflammatory processes (Bessman et al. 2020 ). However, the role and management of a dysregulated iron state in COVID-19 pathogenesis has not yet been addressed.

Increasing evidence shows that inflammation, oxidative stress and altered iron homeostasis are inevitably linked at a systemic level (Kernan and Carcillo 2017) . This perspective elaborates on the potential aspect of altered iron homeostasis, marked by hyper-ferritinemia, and its potential role in COVID-19 pathogenesis and management strategies.

Iron is an essential trace element that plays a role in systemic oxygen transfer, and acts as an electron donor or acceptor in many biological functions. Ferritin is the primary site of iron storage in the cell mainly in its ferric state (Fe3+). Ferritin can carry up to 4500 iron molecules in its core (Kell and Pretorius 2014 Hepcidin, the key iron regulatory hormone, sequesters iron in the enterocytes and macrophages, leading to increased intracellular ferritin, and preventing iron efflux from enterocytes and macrophages (Daher et al. 2017) (Figure 1 ). Thereby, we speculate that increased serum ferritin levels as a result of COVID-19 related hyper-inflammation signifies a vicious cycle of events where increased ferritin levels may lead to further tissue damage (Kell and Pretorius 2014) .

Excess intracellular iron interacts with molecular oxygen, generating reactive oxygen species (ROS) (Kell and Pretorius 2014) . This may largely contribute to oxidative damage of cellular components of different organs (lungs, liver, kidney, heart). Mounting evidence link increased ferritin levels to various inflammatory pathologies including cardiovascular events (Knovich et al. 2009 ). Moreover, the complex interplay between iron metabolism 

Interestingly, recent studies implicated that ferroptosis, which is the process of programmed cell death mediated by iron-dependent peroxidation mechanisms (Ursini and Maiorino 2020) in inflammatory pathologies, involve multiple organs including liver, kidney, heart and lung (Sun et al. 2020) . Ferroptosis was found to be linked to neurological disturbances including cognitive impairment (Sun et al. 2020) , agueusia and anosmia (taste and smell loss) (Osaki et al. 1996; Dinc et al. 2016 ) that are regular manifestations of COVID-19 disease (Vaira et al. 2020) . Iron chelators and ferroptosis inhibitors had protective effects by inhibiting intracellular iron induced lipid peroxidation (Kernan and Carcillo 2017) . The impact of iron overload on extra and intracellular mitochondria dysfunction (Rouault, 2016) , on microbiota dysbiosis (lungs and gut) (Yilmaz and Li. 2018) and on others pathogens, may be strongly implicated as shown in the Figure 1 .

Furthermore, serum coagulability is a major concern in COVID-19 pathogenesis, and rapidly recognized as a key risk factor in susceptible patients (Giannis et al. 2020; Lodigiani et al. 2020; Oxley et al. 2020; Zhang et al. 2020) . In the context of the cellular iron overload, it has long been documented that coagulopathy is a hallmark of iron toxicity. Oxidized iron accelerates serum coagulation by interacting with proteins of coagulation cascade (Jankun et al. 2014 ).

Coagulation and cardiac biomarkers have been described to be elevated in COVID-19 patients; reflecting an inflammatory status characterized by coagulation activation and vascular endothelial dysfunction, found to be predictors of mortality (Giannis et al. 2020; Lodigiani et al. 2020) . A recent report demonstrated acute formation of large vessel strokes in young adults infected with COVID-19 (Oxley et al. 2020) . The inflammation in the blood vessel walls and platelets mitochondria alteration may be driving thrombosis formation (Giannis et al. 2020; Lodigiani et al. 2020; Oxley et al. 2020; Zhang et al. 2020) .

Hyper-ferritinemia observed in COVID-19 patients may be induced in response to inflammation. However, its role in COVID-19 disease progression has not been fully established. It has been reported that hyper-inflammation in association with altered iron homeostasis may play a key role in pathogenesis of disease including viral infections (Drakesmith and Prentice 2008; Schmidt 2020) (Figure 1 ). It may be postulated that hyperferritinemia is associated with a state of iron toxicity which may result from increased ferritin leakage from damaged tissue releasing free iron in the process. There is no established consensus to exclude this possibility. Therefore, it is crucial to investigate coexisting iron parameters in COVID-19 patients including transferrin saturation, plasma iron levels, nontransferrin bound iron (NTBI) as well as hepcidin. The association of hyper-ferritinemia with increased transferrin saturation may reflect a state of iron overload. In this case, we suggest that targeting the intracellular iron overload may be a strategy of vital importance needed to be taken into consideration in future controlled clinical trials.

We suggest, in addition to treatment of the inflammatory state (Moore and June 2020), to envisage the application of approved iron chelators, ferroptosis inhibitors, hepcidin modulators and erythropoietin (Monti et al. 2002; Pinto et al. 2008; Eshagh Hossaini and Haeri 2019; Bessman et al. 2020; Hadadi et al. 2020 ). This promising therapeutic approach can be associated with drugs that specifically target extra and intracellular mitochondria dysfunction or even the reactive species interactome production and ferroptosis (Cortese-Krott et al. 2017; Kernan and Carcillo 2017) (Figure 1 ).

J o u r n a l P r e -p r o o f

Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science (80-)

The Reactive Species Interactome: Evolutionary Emergence, Biological Significance, and Opportunities for Redox Metabolomics and Personalized Medicine

Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease

Does iron deficiency anemia affect olfactory function? Acta Otolaryngol

Viral infection and iron metabolism

Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects

Unusual clotting dynamics of plasma supplemented with iron(III)

Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells

Hyperferritinemia and inflammation

Ferritin for the clinician

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study

COVID-19: consider cytokine storm syndromes and immunosuppression

Does chloroquine really act through oxidative stress?

Cytokine release syndrome in severe COVID-19

Clinical and physiological investigations in patients with taste abnormality

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPα

Mitochondrial iron overload: causes and consequences

The role of iron in viral infections

The emerging role of ferroptosis in inflammation

Lipid peroxidation and ferroptosis: The role of GSH and GPx4

Anosmia and Ageusia: Common Findings in COVID-19 Patients

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

We thank Dr. Laurent Chatre, ISTCT-CNRS, Université de Caen-Normandie, CEA, for his valuable discussions.J o u r n a l P r e -p r o o f